Company profile: Portage Biotech
1.1 - Company Overview
Company description
- Provider of early- to mid-stage oncology therapies, developing adenosine receptor inhibitors (PORT-6 A2A; PORT-7 A2B; PORT-8 dual A2A/A2B; PORT-9 A2B for colorectal/GI) and iNKT-engaging candidates (PORT-2 IMM60 liposomal for refractory NSCLC/melanoma; PORT-3 nanoparticle IMM60+NY-ESO-1). Products are advanced to clinical proof of concept and then sold or licensed for further development.
Products and services
- PORT-8 (TT-53): Dual inhibitor targeting adenosine receptors 2A and 2B for treating solid tumors, combining two receptor targets within one therapy
- Dual-inhibitor class
- PORT-2: Liposomal small-molecule iNKT engager (IMM60) developed for refractory NSCLC and melanoma, employing liposomal delivery to engage invariant natural killer T cells
- Liposomal
- PORT-3: Nanoparticle co-formulation of iNKT engager IMM60 and NY-ESO-1 peptide antigens for solid tumors, co-delivering both components in a single construct
- Nanoparticle-based
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Portage Biotech
GenomeDx
HQ: Canada
Website
- Description: Provider of genomic-based laboratory tests for personalized medicine in cancer care, including the Decipher Prostate Cancer Classifier for independent assessment of tumor aggressiveness, the Decipher GRID genomic expression database in urologic cancer, and genomic testing and a development pipeline focused on creating genomic tests for urologic cancers to aid personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenomeDx company profile →
Vor Bio
HQ: United States
Website
- Description: Provider of immuno-oncology therapies for AML, including VOR33, a gene-edited hematopoietic stem cell therapy lacking CD33 to shield healthy blood cells from targeted therapies, and VCAR33ALLO, an allogeneic anti-CD33 CAR-T for relapsed or refractory post-transplant AML. Runs clinical trials (VBP101, VBP301) and collaborates with blood cancer advocacy groups to support the AML patient community.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vor Bio company profile →
Dendreon
HQ: United States
Website
- Description: Provider of immunotherapy and cell therapy services, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for advanced prostate cancer; end-to-end cell therapy manufacturing; patient operations and logistics to deliver treatments within an 18-hour window across the U.S.; process and analytical development; and cGMP quality assurance and quality control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dendreon company profile →
Tesaro
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical solutions dedicated to improving the lives of cancer patients, leveraging management expertise to identify, acquire and develop promising drug candidates and to commercialize safer, more effective cancer therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tesaro company profile →
Provectus Biopharmaceuticals
HQ: United States
Website
- Description: Provider of investigational therapies for skin, liver, and breast cancers and dermatological conditions, including PV-10, an intratumoral immunotherapy using rose bengal disodium for solid tumors such as melanoma, and PH-10, a topical rose bengal disodium formulation under study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Provectus Biopharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Portage Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Portage Biotech
2.2 - Growth funds investing in similar companies to Portage Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Portage Biotech
4.2 - Public trading comparable groups for Portage Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →